STOCK TITAN

Lucid Diagnostics (LUCD) 424B Filings

LUCD NASDAQ

Here are the 424B prospectus supplements from Lucid Diagnostics Inc. (LUCD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 424B covers the supplement that carries the terms of a priced offering, so if you follow LUCD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LUCD filings page.

Rhea-AI Summary

Lucid Diagnostics is offering 18,000,000 shares of common stock at $1.00 per share. The prospectus supplement states an underwriting discount of $0.06 per share and estimated net proceeds to the company of approximately $16.8 million after underwriting discounts and estimated offering expenses.

Following the offering the company reports 195,253,423 shares of common stock outstanding. The shares are listed on the Nasdaq Capital Market under the symbol LUCD. Officers and directors agreed to 45-day lock-ups after closing. The supplement discloses expected delivery on or about April 24, 2026.

Rhea-AI Summary

Lucid Diagnostics Inc. proposes to offer up to $25,000,000 of common stock through an at-the-market offering under a sales agreement with Maxim Group LLC.

The shares may be sold from time to time at prevailing market prices; Maxim will act as agent or principal and receive a 3.0% commission. Net proceeds, if any, are intended for working capital and general corporate purposes.